Drug Trial Radar · NCT06827613
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Mar 24, 2025
Primary completion
Jan 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Marengo Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Conditions
- Triple Negative Locally Advanced Non-resectable Breast Cancer
- HR+, HER2-, Advanced Breast Cancer
Interventions
STAR0602Drug
solution, intravenous infusion
Sacituzumab Govitecan (SG)Drug
intravenous infusion, 10mg/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 (Safety Run-In): Number of Participants with Dose Limiting Toxicites (DLTs)Time frame: 21 days following the first dose of STAR0602 + Sacituzumab Govitecan
- Phase 1 and 2 (Safety Run-In and Cohort Expansion): Number of Participants with Adverse Events and Serious Adverse EventsTime frame: Up to 3 years
- Phase 1 and 2 (Safety Run-In and Cohort Expansion): Percentage of participants with Overall Objective Tumor Responses (ORR)Time frame: Up to 3 years
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCLA Health
Los Angeles, California · Recruiting
Massachusetts General Hospital Cancer Center
Boston, Massachusetts · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas · Recruiting
BC Cancer
Vancouver, British Columbia, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.